Lupus Therapeutics

Late-Breaking Data at EULAR Shows Investigational Drug Nipocalimab Significantly Reduces Disease Activity in Lupus 

|

Lupus Therapeutics, clinical affiliate of the Lupus Research Alliance, is encouraged by positive late-breaking Phase 2 data with nipocalimab, an investigational drug in development by Johnson & Johnson showing significantly reduced disease activity in adults with moderate-to-severe systemic lupus erythematosus (SLE). These data, part of the JASMINE study, were presented today at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress.  In the JASMINE study, at 52 weeks, nipocalimab plus standard of … Late-Breaking Data at EULAR Shows Investigational Drug Nipocalimab Significantly Reduces Disease Activity in Lupus 

2026 LuCIN Community Meeting Focuses on Integrating Clinical Trials into Day-to-Day Clinical Care 

|

What if clinical trials were not a final option, but a routine part of lupus care?   That question took center stage at the 2026 Lupus Clinical Investigators Network (LuCIN) Community Meeting, where people living with lupus, researchers, clinicians, and industry leaders came together to reshape the future of treatment. LuCIN Investigators (left) and Coordinators join onsite for meaningful … 2026 LuCIN Community Meeting Focuses on Integrating Clinical Trials into Day-to-Day Clinical Care 

Stay Well with Lupus: Tips for Meditation, Movement, and Stress Management 

|

Living with lupus means managing physical symptoms, emotional ups and downs, and the everyday challenges that come with an autoimmune condition. While there’s no one‑size‑fits‑all approach, many people find that caring for both the mind and body can make a meaningful difference.  To help support the lupus community, Lupus Therapeutics, the clinical affiliate of the Lupus … Stay Well with Lupus: Tips for Meditation, Movement, and Stress Management 

Lupus Therapeutics, the Clinical Affiliate of the Lupus Research Alliance, Broadens Proven Peer-to-Peer Program in Clinical Trials

|

Today, Lupus Therapeutics, the clinical affiliate of the Lupus Research Alliance, announced the expansion of its proven peer-to-peer clinical research education program – Patient Advocates for Lupus Studies (PALS) – making it available to hundreds of individuals living with lupus across North America. The expansion builds on the program’s success to date and aims to … Lupus Therapeutics, the Clinical Affiliate of the Lupus Research Alliance, Broadens Proven Peer-to-Peer Program in Clinical Trials

Lupus Research Alliance Showcases Research that will Shape Next Generation Treatments at ACR Convergence 2025 

|

New York, N.Y., October 21, 2025 —  With lupus research accelerating at an unprecedented pace, the Lupus Research Alliance heads to ACR Convergence 2025 (October 24-29, Chicago), the annual meeting of the American College of Rheumatology, to demonstrate how its unique impact across the full research continuum is shaping the next generation of treatments and research.  As the … Lupus Research Alliance Showcases Research that will Shape Next Generation Treatments at ACR Convergence 2025